ニイナミ　ヒロシ   NIINAMI Hiroshi   新浪　博    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	その他
言語種別	英語
査読の有無	査読なし
表題	Novel Scoring System to Risk Stratify Patients Receiving Durable Left Ventricular Assist Device From J-MACS Registry Data.
掲載誌名	正式名：Circulation journal : official journal of the Japanese Circulation Society 略　 称：Circ J ISSNコード：13474820/13469843
掲載区分	国外
巻・号・頁	87(8),pp.1103-1111
著者・共著者	Imamura Teruhiko†, Kinugawa Koichiro, Nishimura Takashi, Toda Koichi, Saiki Yoshikatsu, Niinami Hiroshi, Nunoda Shinichi, Matsumiya Goro, Nishimura Motonobu, Arai Hirokuni, Yanase Masanobu, Fukushima Norihide, Nakatani Takeshi, Shiose Akira, Shibasaki Ikuko, Sakata Yasushi, Ono Minoru,
発行年月	2023/07/25
概要	BACKGROUND:Recently, destination therapy (DT) was approved in Japan, and patients ineligible for heart transplantation may now receive durable left ventricular assist devices (LVADs). Several conventional risk scores are available, but a risk score that is best to select optimal candidates for DT in the Japanese population remains unestablished.Methods and Results: A total of 1,287 patients who underwent durable LVAD implantation and were listed for the Japanese registry for Mechanically Assisted Circulatory Support (J-MACS) were eligible for inclusion. Finally, 494 patients were assigned to the derivation cohort and 487 patients were assigned to the validation cohort. According to the time-to-event analyses, J-MACS risk scores were newly constructed to predict 3-year mortality rate, consisting of age, history of cardiac surgery, serum creatinine level, and central venous pressure to pulmonary artery wedge pressure ratio >0.71. The J-MACS risk score had the highest predictability of 3-year death compared with other conventional scores in the validation cohort, including HeartMate II risk score and HeartMate 3 risk score.CONCLUSIONS:We constructed the J-MACS risk score to estimate 3-year mortality rate after durable LVAD implantation using large-scale multicenter Japanese data. The clinical utility of this scoring to guide the indication of DT should be validated in the next study.
DOI	10.1253/circj.CJ-23-0264
PMID	37258218